Spatial immune remodeling during neoadjuvant therapy in hepatocellular carcinoma: Mechanisms, clinical implications, and future perspectives
- 1Tsinghua Medicine, Tsinghua University, Beijing 100084, China
- 2Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China
- 3Department of Pathology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China
Abstract
Neoadjuvant therapy is an emerging strategy for hepatocellular carcinoma (HCC), particularly in cases with technically resectable but biologically high-risk disease. Neoadjuvant therapy aims to reduce tumor burden and postoperative recurrence risk in high-risk HCC, while also providing a unique opportunity to preoperatively remodel the tumor microenvironment (TME). Recent advances in spatial multiomics have shown that the HCC immune microenvironment is highly heterogeneous, with distinct immune landscapes across the tumor core, invasive front, and adjacent liver tissue. At the spatial level, neoadjuvant therapy may reorganize the HCC tumor microenvironment beyond simple changes in immune-cell abundance. It reshapes the localization and interaction networks of tumor, immune, stromal, and vascular cells, including immune-cell infiltration into tumor nests, tumor–immune cell proximity, vascular accessibility, fibrotic exclusion barriers, and residual resistant niches. Collectively, these spatial changes influence pathological response, microvascular invasion, recurrence risk, and perioperative decision-making. However, key challenges include optimal patient selection, response evaluation, treatment sequencing, surgery timing, and perioperative safety management. Future integration of spatial omics, ctDNA, radiomics, digital pathology, and artificial intelligence may enable further developments in biology-guided neoadjuvant therapy and precise perioperative management of HCC.
Related
- Synergistic strategies of tumor ablation and immunotherapy in hepatocellular carcinoma: mechanisms, clinical translation, and perspectives
- Osteoimmunology and bone microenvironment remodeling in osteoporosis: mechanisms and translational perspectives
- Malignant remodeling of the bone marrow microenvironment in acute myeloid leukemia: mechanisms and therapeutic implications
- Dynamic Urothelial Remodeling in Diabetic Bladder Dysfunction: Disease-Course Changes, Molecular Mechanisms, and Clinical Implications
- Aldosterone-Mediated Atrial Remodeling and Atrial Fibrillation: Molecular Mechanisms, Translational Insights and Implications for Cardiac Surgery
BibTeX
@article{yang2026spatial,
title = {{Spatial immune remodeling during neoadjuvant therapy in hepatocellular carcinoma: Mechanisms, clinical implications, and future perspectives}},
author = {Ruiqi Yang and Fansen Ji and Hongxuan Li and Ying Xiao and Jianghui Yang and Bingjun Tang and Huan Li and Hao Chen and Hongfang Yin and Shizhong Yang and Jiahong Dong},
journal = {ILIVER},
year = {2026},
month = oct,
doi = {10.1016/j.iliver.2026.100274},
url = {https://doi.org/10.1016/j.iliver.2026.100274},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Spatial immune remodeling during neoadjuvant therapy in hepatocellular carcinoma: Mechanisms, clinical implications, and future perspectives
AU - Ruiqi Yang
AU - Fansen Ji
AU - Hongxuan Li
AU - Ying Xiao
AU - Jianghui Yang
AU - Bingjun Tang
AU - Huan Li
AU - Hao Chen
AU - Hongfang Yin
AU - Shizhong Yang
AU - Jiahong Dong
PY - 2026
DA - 2026/10/02
JO - ILIVER
DO - 10.1016/j.iliver.2026.100274
UR - https://doi.org/10.1016/j.iliver.2026.100274
AB - Neoadjuvant therapy is an emerging strategy for hepatocellular carcinoma (HCC), particularly in cases with technically resectable but biologically high-risk disease. Neoadjuvant therapy aims to reduce tumor burden and postoperative recurrence risk in high-risk HCC, while also providing a unique opportunity to preoperatively remodel the tumor microenvironment (TME). Recent advances in spatial multiomics have shown that the HCC immune microenvironment is highly heterogeneous, with distinct immune landscapes across the tumor core, invasive front, and adjacent liver tissue. At the spatial level, neoadjuvant therapy may reorganize the HCC tumor microenvironment beyond simple changes in immune-cell abundance. It reshapes the localization and interaction networks of tumor, immune, stromal, and vascular cells, including immune-cell infiltration into tumor nests, tumor–immune cell proximity, vascular accessibility, fibrotic exclusion barriers, and residual resistant niches. Collectively, these spatial changes influence pathological response, microvascular invasion, recurrence risk, and perioperative decision-making. However, key challenges include optimal patient selection, response evaluation, treatment sequencing, surgery timing, and perioperative safety management. Future integration of spatial omics, ctDNA, radiomics, digital pathology, and artificial intelligence may enable further developments in biology-guided neoadjuvant therapy and precise perioperative management of HCC.
SN - 2772-9478
ER -